DE602007009713D1 - Cross-spot - Google Patents

Cross-spot

Info

Publication number
DE602007009713D1
DE602007009713D1 DE602007009713T DE602007009713T DE602007009713D1 DE 602007009713 D1 DE602007009713 D1 DE 602007009713D1 DE 602007009713 T DE602007009713 T DE 602007009713T DE 602007009713 T DE602007009713 T DE 602007009713T DE 602007009713 D1 DE602007009713 D1 DE 602007009713D1
Authority
DE
Germany
Prior art keywords
spot
cross
immune effector
antigen
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007009713T
Other languages
English (en)
Inventor
Ailko Wim Jan Bossink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE602007009713D1 publication Critical patent/DE602007009713D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5052—Cells of the immune system involving B-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
DE602007009713T 2006-10-16 2007-10-16 Cross-spot Active DE602007009713D1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85176506P 2006-10-16 2006-10-16
EP06122334 2006-10-16
PCT/NL2007/050498 WO2008048097A1 (en) 2006-10-16 2007-10-16 Cross-spot

Publications (1)

Publication Number Publication Date
DE602007009713D1 true DE602007009713D1 (en) 2010-11-18

Family

ID=37495887

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007009713T Active DE602007009713D1 (en) 2006-10-16 2007-10-16 Cross-spot

Country Status (5)

Country Link
US (1) US20110059430A1 (de)
EP (1) EP2080024B1 (de)
AT (1) ATE483973T1 (de)
DE (1) DE602007009713D1 (de)
WO (1) WO2008048097A1 (de)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ214400A (en) * 1985-12-02 1989-05-29 Univ Otago Detecting infection in ruminant including conducting assay of mononuclear cell function
US6284255B1 (en) * 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections

Also Published As

Publication number Publication date
EP2080024B1 (de) 2010-10-06
US20110059430A1 (en) 2011-03-10
ATE483973T1 (de) 2010-10-15
EP2080024A1 (de) 2009-07-22
WO2008048097A1 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
PH12016500658B1 (en) Human anti-alpha-synuclein autoantibodies
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
TW200716646A (en) (S)-N-methylnaltrexone
PH12015500125A1 (en) Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
MX2009011500A (es) Anticuerpos anti-mdl-1.
EP2517557A3 (de) Tiermodelle und therapeutische Moleküle
MY171841A (en) Antibody formulation
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
PH12015500243B1 (en) Glycoconjugation processes and compositions
CY1115935T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
EP2321430B8 (de) Verfahren zur bewertung des oralkarzinomrisikos bei menschen
WO2011157741A3 (en) Human antibody drug conjugates against tissue factor
NO20083891L (no) Anti-5T4 antistoffer og anvendelser derav
UA92505C2 (ru) Композиции на основе антитела против cd3
BR122018069446B8 (pt) método in vitro para detectar a presença de um célula de câncer em um indivíduo
MX2007012702A (es) Uso de anticuerpos cd25 en inmunoterapia.
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
MA33537B1 (fr) Anticorps anti-cdcp1 humanisés
MX2008008185A (es) Antigenos de acido des-n-acetil-sialico, anticuerpos para los mismos, y metodos de uso en la terapia de cancer.
NZ592994A (en) Diagnostic test for Streptococcus equi comprising assessing the presence or absence of the S. equi eqbE gene
WO2010028373A3 (en) Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients
WO2010031749A9 (en) Compositions and methods for detecting tlr3
WO2011112670A3 (en) Methods and compositions for chlamydial antigens for diagnosis and treatment of chlamydial infection and disease
WO2007054537A8 (en) Novel bacterium and vaccine